Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocular Therapeutix (OCUL) granted equity awards to Tiffany Howard, its new Executive Vice President, Commercial – Retina, effective November 16, 2026. The awards were an inducement for Howard to accept employment and were granted under the 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Howard received a ten-year option to buy up to 200,000 common shares at $6.01 per share, the closing price on the grant date, and restricted stock units covering 65,000 common shares. The option vests over four years and the units over three, both subject to continued service through the applicable vesting dates.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Ten-year stock option could dilute shareholders by up to 200,000 common shares if exercised at $6.01 per share
- Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units could dilute shareholders by 65,000 common shares, with vesting over three years subject to continued service
Key Figures
- Stock options
- up to 200,000 shares
- Inducement award
- Restricted stock units
- 65,000 shares
- Inducement award
- Option exercise price
- $6.01 per share
- Equal to the closing price on the grant’s effective date
- Option term
- ten years
- Stock option award
- Option vesting
- over four years
- 25% vests on the first anniversary; the remainder vests in equal monthly installments over the next three years
- RSU vesting
- over three years
- Equal annual installments on the first, second and third grant anniversaries
Historical Context
-
Eight new employees received stock options and restricted stock units under the inducement plan.
-
Fifteen new employees received stock options and restricted stock units under the inducement plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-statutory stock option financial
restricted stock unit financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company’s new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of November 16, 2026, and consist of a non-statutory stock option award to purchase up to 200,000 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 65,000 shares of Ocular’s common stock. The stock option award has an exercise price of
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.